H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of MapLight Therapeutics with a Buy rating and $45 price target. MapLight is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, the analyst tells investors in a research note. The firm believes MapLight's lead candidate could generate peak sales approaching $4B annually if approved in both schizophrenia and Alzheimer's disease psychosis.
